Login to Your Account



Clinic Roundup


Friday, August 3, 2012
• DBV Technologies, of Bagneux, France, said the first patient has been enrolled in the VIPES Phase IIb study of Viaskin, an epicutaneous immunotherapy approach to desensitizing against peanut allergy via a skin patch. A total of 220 peanut-allergic subjects, ranging in age from 6 to 55, with a history of immediate hypersensitive reaction to peanut protein, will be enrolled in the study.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription